Investor enthusiasm, AI tie-ups stand out at JP Morgan Healthcare Conference: We expect future investment activity to be driven by the AI arms race taking place across the healthcare and pharma industries.
Could Trump’s second term include a ban on D2C pharma ads? We examine the likelihood of a ban and explore what more oversight of drug ads on TV means for pharma marketers.
Hippocratic AI rolls out AI agent app store: Licensed US clinicians can use the store to create “AI agents” that carry out certain clinical tasks, helping to augment their work and free up time for direct patient care.
Walgreens’ Q1 earnings report sends shares soaring: For its Q1 turnaround to translate into long-term success, the company will need to foster an improved experience that convinces customers to actually step foot in its stores.
New rule removes medical debt from credit reports: While this will help in terms of approval and interest rates for loans, relief won’t be felt until health systems stop aggressively chasing down patients’ unpaid bills.
Transcarent to acquire Accolade for $621M: The deal could lower costs for employer and health plan customers. It’s also an indicator that more digital health M&As will take place in 2025.
Meta’s healthcare ad changes go into effect: Healthcare advertisers will need to get creative and experiment with different approaches to effectively reach their target audiences in light of the changes.
Pharma is forecast for positive momentum in 2025: But increases in drug approvals and product sales are no guarantee as the US transitions to a new administration.
UPS pushes into healthcare logistics: The company is renting out custom lab space near its main global air hub. Diagnostics companies will be able to consolidate their shipping operations and drive downstream cost-savings.
Withings unveils AI-enabled smart mirror at CES: But consumers’ low interest in prior smart mirror products isn't likely to change.
Americans blame health insurers for UHC CEO assassination: Now more than ever, healthcare marketers, PR professionals, and industry leaders need to be transparent about why healthcare costs are so high, while offering realistic solutions to drive change.
Some health systems expand local pharmacy services: But it’s not enough to fill gaps created by thousands of drugstore closings. We expect more consumers to explore alternative pharmacy offerings in 2025.
Households with GLP-1 users slash their spending on groceries: Food companies need to adapt to the shifting buying patterns of consumers on GLP-1s to stay competitive.
Over a quarter (27.9%) of US internet users use mobile apps to track their fitness and health, according to October 2024 data from Comscore.
US consumers see weight loss drugs as more effective than diet, exercise: Many plan to take a GLP-1 in 2025. Marketers in the health, wellness, and fitness spaces must pounce on the opportunity to frame their offerings as a better long-term bet than weight loss drugs.
Drugmakers plan price hikes on over 250 branded medications in US: Facing a hit under the Inflation Reduction Act, they’re taking matters into their own hands to offset lost revenue.
Consumers don’t want to pay for patient portal messages: And responding to messages takes up physicians’ ever-limited time. Here’s how AI chatbots could benefit both parties.
Keep it simple, smart, and familiar: Forget futuristic pendants and pins—AI wearables that look like regular gear but pack powerful features will be the ones capturing market share in 2025.
RFK Jr.’s pharmaceutical ad ban could affect $22 billion in ad spending: A business-friendly Trump administration could hamper RFK’s plans to cut D2C advertising.
Trump plans to “knock out” pharma’s middlemen: His comments sent shares of the three largest pharmacy benefit managers down in a sign of what’s to come under the incoming administration.